Reena Patel, DO
Allergy & Immunology · Memphis, TNNPI 1669821187
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,630 of the $100,514 with a category attached, or 82.2%. AstraZeneca accounts for 93.0% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $56,908, more than ten times the $15 reported in 2021. Among allergy & immunology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 468 payments — averaging $214.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$93K
- GSK$2K
- Genentech USA, Inc.$934
- CSL Behring$840
- Novartis$748
- Sanofi$542
- plus $2K from 19 others
What the payments were for
- Consulting fees$4,5345%
- Speaking & faculty fees$82,63082%
- Travel & lodging$2,6463%
- Food & beverage$10,68711%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 148 | $93,471 |
| GSK | 99 | $1,640 |
| Genentech USA, Inc. | 43 | $934 |
| CSL Behring | 28 | $840 |
| Novartis | 33 | $748 |
| Sanofi | 23 | $542 |
| Regeneron Healthcare Solutions, Inc. | 17 | $409 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $335 |
| Octapharma USA, Inc. | 16 | $316 |
| Amgen | 11 | $206 |
| LEO Pharma Inc. | 7 | $186 |
| Pfizer | 8 | $152 |
| AbbVie | 1 | $104 |
| Grifols USA, LLC | 5 | $103 |
| Organon | 2 | $96 |
| Genentech, Inc. | 1 | $88 |
| Teva Pharmaceuticals USA, Inc. | 2 | $81 |
| Kaleo, Inc. | 4 | $73 |
| Lilly USA, LLC | 2 | $39 |
| Cycle Pharmaceuticals Inc | 1 | $31 |
| GC Biopharma USA, Inc. | 1 | $29 |
| Biocryst US Sales Co., LLC | 1 | $28 |
| Dermavant Sciences, Inc. | 1 | $26 |
| Ionis Pharmaceuticals, Inc. | 1 | $22 |
| Galderma Laboratories, L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$100,514 in reported general payments places this provider in the 90th percentile of 79 allergy & immunology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 18 | $63,194 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $61,975 |
| XolairOmalizumab | 19 | $58,153 |
| Dupixent PenDupilumab | 14 | $53,547 |
| XembifyImmune Globulin,gamma(Igg)klhw | 12 | $45,837 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $32,455 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $20,392 |
| Epinephrine | 62 | $14,470 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $9,392 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,136 |
| AirsupraAlbuterol Sulfate/Budesonide | 11 | $5,105 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,950 |
| Azelastine Hcl | 114 | $2,657 |
| Ipratropium Bromide | 59 | $2,162 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $1,640 | $145,561144 claims |
| Genentech, Inc.Xolair | $88 | $58,15319 claims |
| Grifols USA, LLCXembify | $103 | $45,83712 claims |
| AstraZenecaBreztri Aerosphere, Airsupra, Symbicort | $93,471 | $41,51072 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 79 allergy & immunology providers in Tennessee.
Other allergy & immunology in Memphis
- Phillip LiebermanMemphis$131K
- Jay LiebermanMemphis$81K
- Amy RagsdaleMemphis$8K
- Venusa PhomakayMemphis$6K
- Phuong leMemphis$3K
- Nicholas KolinskyKnoxville$472K
- Tidence PrinceMaryville$269K
- Tammy Heinly McCulleyGermantown$165K
- John FahrenholzNashville$124K
- Marc CromieChattanooga$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.